BRPI0508053A - método de combater toxicidade causada por um composto antifolato, e de tratar uma doença, usos de enzima que possui atividade de carbóxi-peptidase g, de composto antifolato, de agente de resgate de rota de folato, e de enzima que possui atividade de carbóxi-peptidase g e de um agente de resgate de rota de folato, sistema terapêutico, e, método ex vivo de clivar um grupo l-glutamato terminal de um composto, de determinar a taxa e/ou extenção de clivagem de um composto, e de clivagem de um composto - Google Patents
método de combater toxicidade causada por um composto antifolato, e de tratar uma doença, usos de enzima que possui atividade de carbóxi-peptidase g, de composto antifolato, de agente de resgate de rota de folato, e de enzima que possui atividade de carbóxi-peptidase g e de um agente de resgate de rota de folato, sistema terapêutico, e, método ex vivo de clivar um grupo l-glutamato terminal de um composto, de determinar a taxa e/ou extenção de clivagem de um composto, e de clivagem de um compostoInfo
- Publication number
- BRPI0508053A BRPI0508053A BRPI0508053-3A BRPI0508053A BRPI0508053A BR PI0508053 A BRPI0508053 A BR PI0508053A BR PI0508053 A BRPI0508053 A BR PI0508053A BR PI0508053 A BRPI0508053 A BR PI0508053A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- activity
- folate
- peptidase
- enzyme
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
"MéTODOS DE COMBATER TOXICIDADE CAUSADA POR UM COMPOSTO ANTIFOLATO, E DE TRATAR UMA DOENçA, USOS DE ENZIMA QUE POSSUI ATIVIDADE DE CARBóXI-PEPTIDASE G, DE COMPOSTO ANTIFOLATO, DE AGENTE DE RESGATE DE ROTA DE FOLATO, E DE ENZIMA QUE POSSUI ATIVIDADE DE CARBóXIPEPTIDASE G E DE UM AGENTE DE RESGATE DE ROTA DE FOLATO, SISTEMA TERAPêUTICO, E, MéTODOS EX VIVO DE CLIVAR UM GRUPO L-GLUTAMATO TERMINAL DE UM COMPOSTO, DE DETERMINAR A TAXA E/OU EXTENSãO DE CLIVAGEM DE UM COMPOSTO, E DE CLIVAGEM DE UM COMPOSTO" Um método de combater toxicidade causada por um composto antifolato de Fórmula (l), em um indivíduo que tem sido administrado com o composto. O método compreende administrar ao indivíduo uma enzima que possui atividade de carbóxi-peptidase G. Um método de clivagem de um composto compreendendo um fragmento estrutural de Fórmula (VIII) o método compreendendo contatar o composto compreendendo o fragmento estrutural de Fórmula (VIII) com uma enzima que possui atividade de carbóxi-peptidase G.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0404487.1A GB0404487D0 (en) | 2004-02-28 | 2004-02-28 | Use of enzyme |
PCT/GB2005/000751 WO2005084695A2 (en) | 2004-02-28 | 2005-02-28 | Use of carboxypeptidase g for combating antifolate toxicity |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0508053A true BRPI0508053A (pt) | 2007-07-17 |
Family
ID=32051060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0508053-3A BRPI0508053A (pt) | 2004-02-28 | 2005-02-28 | método de combater toxicidade causada por um composto antifolato, e de tratar uma doença, usos de enzima que possui atividade de carbóxi-peptidase g, de composto antifolato, de agente de resgate de rota de folato, e de enzima que possui atividade de carbóxi-peptidase g e de um agente de resgate de rota de folato, sistema terapêutico, e, método ex vivo de clivar um grupo l-glutamato terminal de um composto, de determinar a taxa e/ou extenção de clivagem de um composto, e de clivagem de um composto |
Country Status (13)
Country | Link |
---|---|
US (1) | US20070243182A1 (pt) |
EP (1) | EP1727548A2 (pt) |
JP (1) | JP2007524711A (pt) |
KR (1) | KR20070036023A (pt) |
CN (1) | CN1950088A (pt) |
AU (1) | AU2005218987A1 (pt) |
BR (1) | BRPI0508053A (pt) |
CA (1) | CA2557610A1 (pt) |
GB (1) | GB0404487D0 (pt) |
IL (1) | IL177647A0 (pt) |
MX (1) | MXPA06009711A (pt) |
WO (1) | WO2005084695A2 (pt) |
ZA (1) | ZA200607171B (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007023243A2 (en) * | 2005-08-24 | 2007-03-01 | Protherics Medicines Development Limited | Cleavage of antifolate compounds |
US7658913B2 (en) | 2005-11-28 | 2010-02-09 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing nephrotoxicity and methods of use thereof |
US20100260825A1 (en) * | 2009-04-13 | 2010-10-14 | Nair Madhavan G | Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches |
EP2266984A1 (en) * | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis |
US8404859B2 (en) | 2011-03-16 | 2013-03-26 | Hoffmann-La Roche Inc. | Thiazole and thiophene compounds |
EP4313314A1 (en) * | 2021-03-30 | 2024-02-07 | Genecentric Therapeutics, Inc. | Methods for assessing proliferation and anti-folate therapeutic response |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0011060D0 (en) * | 2000-05-08 | 2000-06-28 | Cancer Res Campaign Tech | Improvements relating to gene directed enzyme prodrug therapy |
-
2004
- 2004-02-28 GB GBGB0404487.1A patent/GB0404487D0/en not_active Ceased
-
2005
- 2005-02-28 EP EP05717830A patent/EP1727548A2/en not_active Withdrawn
- 2005-02-28 BR BRPI0508053-3A patent/BRPI0508053A/pt not_active IP Right Cessation
- 2005-02-28 JP JP2007500299A patent/JP2007524711A/ja not_active Withdrawn
- 2005-02-28 KR KR1020067017341A patent/KR20070036023A/ko not_active Application Discontinuation
- 2005-02-28 ZA ZA200607171A patent/ZA200607171B/en unknown
- 2005-02-28 AU AU2005218987A patent/AU2005218987A1/en not_active Abandoned
- 2005-02-28 CN CNA200580013842XA patent/CN1950088A/zh active Pending
- 2005-02-28 MX MXPA06009711A patent/MXPA06009711A/es unknown
- 2005-02-28 WO PCT/GB2005/000751 patent/WO2005084695A2/en active Application Filing
- 2005-02-28 US US10/590,789 patent/US20070243182A1/en not_active Abandoned
- 2005-02-28 CA CA002557610A patent/CA2557610A1/en not_active Abandoned
-
2006
- 2006-08-22 IL IL177647A patent/IL177647A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2005084695A2 (en) | 2005-09-15 |
CN1950088A (zh) | 2007-04-18 |
KR20070036023A (ko) | 2007-04-02 |
GB0404487D0 (en) | 2004-03-31 |
ZA200607171B (en) | 2007-11-28 |
MXPA06009711A (es) | 2007-05-16 |
US20070243182A1 (en) | 2007-10-18 |
AU2005218987A1 (en) | 2005-09-15 |
EP1727548A2 (en) | 2006-12-06 |
IL177647A0 (en) | 2007-07-04 |
CA2557610A1 (en) | 2005-09-15 |
WO2005084695A3 (en) | 2005-12-08 |
JP2007524711A (ja) | 2007-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0520493A2 (pt) | usos de uma enzima, de um composto antifolato e de um agente de resgate de rota de folato, sistema terapêutico, e, métodos ex vivo para clivar um grupo l-glutamato terminal de um composto, para determinar a taxa e/ou extensão de clivagem de um composto e para clivar um composto | |
SG146653A1 (en) | Methods and reagents for the treatment of immunoinflammatory disorders | |
DE60111539D1 (de) | Pharmazeutische zusammensetzung enthaltend ein 5-aminolaevulinsäure-ester als photochemotherapeutikum und ein mucoadhäsivum | |
BRPI0410041A (pt) | métodos para tratamento de dor de cabeça de sinusite | |
BR0114799A (pt) | Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos | |
WO2005037203A3 (en) | Methods and reagents for the treatment of immunoinflammatory disorders | |
BRPI0407897A (pt) | derivados de cianopiridina úteis no tratamento de cáncer e outros distúrbios | |
EE200200578A (et) | Antihüpertensiivsete ja antiangiogeensete ainete terapeutilised kombinatsioonid | |
WO2001087328A3 (en) | Interleukin-1 inhibitors in the treatment of diseases | |
NO20053855D0 (no) | 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer. | |
BRPI0508053A (pt) | método de combater toxicidade causada por um composto antifolato, e de tratar uma doença, usos de enzima que possui atividade de carbóxi-peptidase g, de composto antifolato, de agente de resgate de rota de folato, e de enzima que possui atividade de carbóxi-peptidase g e de um agente de resgate de rota de folato, sistema terapêutico, e, método ex vivo de clivar um grupo l-glutamato terminal de um composto, de determinar a taxa e/ou extenção de clivagem de um composto, e de clivagem de um composto | |
BRPI0013010B8 (pt) | formulação aquosa de cloreto de sódio de moxifloxacina, processo para sua preparação e aplicação da referida formulação, bem como preparado de combinação e aplicação de uma solução aquosa de cloridrato de moxifloxacina | |
BRPI0406883A (pt) | Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
BR9814923A (pt) | Método para tratamento de doença de alzheimer | |
ATE531419T1 (de) | Vorrichtung zur verabreichung von therapeutischen mitteln | |
PE20110711A1 (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma | |
NO20024646D0 (no) | Kombinasjonsterapier med vaskul¶r-skadende aktivitet | |
IT1314185B1 (it) | Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi | |
BRPI0406858A (pt) | Liberação controlada de agentes altamente solúveis | |
BRPI0409796A (pt) | uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina | |
BR0313413A (pt) | Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer | |
SE0102147D0 (sv) | New methods | |
BRPI0506630A (pt) | composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada | |
WO2008021048A3 (en) | Adp-ribosyltransferase based methods and compositions | |
BR0112131A (pt) | Composições farmacêuticas e métodos para uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |